Bioxytran, Inc. (BIXT)
USD 0.15
(2.09%)
USD 0.15
(2.09%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 1.92 Million USD | -11.09% |
| 2022 | 2.16 Million USD | 2.02% |
| 2021 | 2.12 Million USD | 31.62% |
| 2020 | 1.61 Million USD | 89.47% |
| 2019 | 850.98 Thousand USD | 274.26% |
| 2018 | 227.37 Thousand USD | 106.71% |
| 2017 | 110 Thousand USD | 0.0% |
| 2016 | 110 Thousand USD | 0.0% |
| 2015 | 110 Thousand USD | 0.0% |
| 2014 | 110 Thousand USD | -9.09% |
| 2013 | 121 Thousand USD | 245.71% |
| 2012 | 35 Thousand USD | 0.0% |
| 2011 | 35 Thousand USD | -47.86% |
| 2010 | 67.13 Thousand USD | -28.96% |
| 2009 | 94.49 Thousand USD | 2204.76% |
| 2008 | 4100.00 USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q3 | 933.58 Thousand USD | 11.28% |
| 2024 Q2 | 838.97 Thousand USD | -13.74% |
| 2024 Q1 | 972.6 Thousand USD | -49.47% |
| 2023 Q3 | 1.92 Million USD | -3.75% |
| 2023 Q1 | 2.16 Million USD | 0.0% |
| 2023 FY | 1.92 Million USD | -11.09% |
| 2023 Q4 | 1.92 Million USD | 0.0% |
| 2023 Q2 | 2 Million USD | -7.62% |
| 2022 Q1 | 3.55 Million USD | 67.39% |
| 2022 Q2 | 3.59 Million USD | 1.17% |
| 2022 Q3 | 2.15 Million USD | -39.96% |
| 2022 Q4 | 2.16 Million USD | 0.35% |
| 2022 FY | 2.16 Million USD | 2.02% |
| 2021 Q3 | 2.09 Million USD | 1.45% |
| 2021 FY | 2.12 Million USD | 31.62% |
| 2021 Q4 | 2.12 Million USD | 1.43% |
| 2021 Q1 | 2.03 Million USD | 26.1% |
| 2021 Q2 | 2.06 Million USD | 1.43% |
| 2020 Q1 | 1.71 Million USD | 101.97% |
| 2020 Q3 | 1.61 Million USD | 0.51% |
| 2020 FY | 1.61 Million USD | 89.47% |
| 2020 Q4 | 1.61 Million USD | -0.04% |
| 2020 Q2 | 1.6 Million USD | -6.62% |
| 2019 Q1 | 742.69 Thousand USD | 226.63% |
| 2019 FY | 850.98 Thousand USD | 274.26% |
| 2019 Q2 | 633.21 Thousand USD | -14.74% |
| 2019 Q3 | 589.27 Thousand USD | -6.94% |
| 2019 Q4 | 850.98 Thousand USD | 44.41% |
| 2018 Q2 | 110 Thousand USD | 0.0% |
| 2018 Q3 | - USD | -100.0% |
| 2018 Q1 | 110 Thousand USD | 0.0% |
| 2018 FY | 227.37 Thousand USD | 106.71% |
| 2018 Q4 | 227.37 Thousand USD | 0.0% |
| 2017 Q2 | 110.34 Thousand USD | 0.32% |
| 2017 FY | 110 Thousand USD | 0.0% |
| 2017 Q3 | 110 Thousand USD | -0.32% |
| 2017 Q4 | 110 Thousand USD | 0.0% |
| 2017 Q1 | 110 Thousand USD | 0.0% |
| 2016 Q2 | 110 Thousand USD | 0.0% |
| 2016 FY | 110 Thousand USD | 0.0% |
| 2016 Q4 | 110 Thousand USD | 0.0% |
| 2016 Q3 | 110 Thousand USD | 0.0% |
| 2016 Q1 | 110 Thousand USD | 0.0% |
| 2015 Q4 | 110 Thousand USD | 4.76% |
| 2015 FY | 110 Thousand USD | 0.0% |
| 2015 Q1 | 110 Thousand USD | 0.0% |
| 2015 Q2 | 115.67 Thousand USD | 5.16% |
| 2015 Q3 | 105 Thousand USD | -9.23% |
| 2014 Q1 | 115 Thousand USD | -4.96% |
| 2014 FY | 110 Thousand USD | -9.09% |
| 2014 Q4 | 110 Thousand USD | -4.35% |
| 2014 Q3 | 115 Thousand USD | 0.0% |
| 2014 Q2 | 115 Thousand USD | 0.0% |
| 2013 Q4 | 121 Thousand USD | 5.22% |
| 2013 FY | 121 Thousand USD | 245.71% |
| 2013 Q1 | 42 Thousand USD | 20.0% |
| 2013 Q2 | 115 Thousand USD | 173.81% |
| 2013 Q3 | 115 Thousand USD | 0.0% |
| 2012 Q4 | 35 Thousand USD | 0.0% |
| 2012 FY | 35 Thousand USD | 0.0% |
| 2012 Q1 | 35 Thousand USD | 0.0% |
| 2012 Q2 | 35 Thousand USD | 0.0% |
| 2012 Q3 | 35 Thousand USD | 0.0% |
| 2011 Q2 | 50 Thousand USD | 0.0% |
| 2011 FY | 35 Thousand USD | -47.86% |
| 2011 Q3 | 45 Thousand USD | -10.0% |
| 2011 Q4 | 35 Thousand USD | -22.22% |
| 2011 Q1 | 50 Thousand USD | -25.52% |
| 2010 Q3 | 68.94 Thousand USD | -27.6% |
| 2010 Q2 | 95.21 Thousand USD | 0.0% |
| 2010 Q1 | 95.21 Thousand USD | 0.77% |
| 2010 FY | 67.13 Thousand USD | -28.96% |
| 2010 Q4 | 67.13 Thousand USD | -2.62% |
| 2009 FY | 94.49 Thousand USD | 2204.76% |
| 2009 Q2 | 2100.00 USD | -85.11% |
| 2009 Q3 | 52.88 Thousand USD | 2418.33% |
| 2009 Q1 | 14.1 Thousand USD | 0.0% |
| 2009 Q4 | 94.49 Thousand USD | 78.68% |
| 2008 FY | 4100.00 USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -653.153% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -43.274% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -56.713% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 95.562% |
| GB Sciences, Inc. | 1.75 Million USD | -9.418% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Skye Bioscience, Inc. | 4.61 Million USD | 58.291% |
| Zenith Capital Corp. | 10.22 Thousand USD | -18726.406% |
| Agentix Corp. | 50 Thousand USD | -3750.0% |
| Arch Therapeutics, Inc. | 5.87 Million USD | 67.212% |
| Biomind Labs Inc. | 735.54 Thousand USD | -161.712% |
| ContraFect Corporation | 2.88 Million USD | 33.183% |
| CSL Limited | 12.18 Billion USD | 99.984% |
| CytoDyn Inc. | 30.07 Million USD | 93.6% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -435.153% |
| Neon Bloom, Inc. | 630.07 Thousand USD | -205.518% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 95.775% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | -103.001% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -154.561% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 93.533% |
| SQZ Biotechnologies Company | 27.47 Million USD | 92.993% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | -116.764% |
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 95.328% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | 17.238% |
| Mesoblast Limited | 118.7 Million USD | 98.378% |
| Marizyme, Inc. | 18.71 Million USD | 89.716% |
| Genus plc | 233.1 Million USD | 99.174% |
| Pharming Group N.V. | 171.54 Million USD | 98.878% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | -156.667% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | -33.097% |
| IMV Inc. | 28.88 Million USD | 93.335% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | 65.979% |
| MultiCell Technologies, Inc. | 202.58 USD | -950141.88% |
| ONE Bio Corp. | 19.71 Million USD | 90.236% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 96.652% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 94.184% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | 36.389% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | 85.189% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -1260.251% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -7384.739% |
| Alpha Cognition Inc. | 1.22 Million USD | -57.739% |
| Enzolytics Inc. | 996.33 Thousand USD | -93.208% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 20 Million USD | 90.375% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 72.783% |
| Genscript Biotech Corporation | 417.73 Million USD | 99.539% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | 53.299% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -379.036% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | 19.716% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -739.545% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -1194.953% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | 34.309% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -1320.801% |
| Adynxx, Inc. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.49 Million USD | -28.784% |
| Q BioMed Inc. | 4.1 Million USD | 53.163% |
| Capstone Therapeutics Corp. | 20.32 Million USD | 90.53% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 97.154% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| BioStem Technologies, Inc. | 4.71 Million USD | 59.142% |
| Curative Biotechnology, Inc. | 2.25 Million USD | 14.762% |
| HST Global, Inc. | 98.31 Thousand USD | -1857.913% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -673.963% |
| Halberd Corporation | 150 Thousand USD | -1183.333% |
| Resverlogix Corp. | 6.49 Million USD | 70.344% |
| Cell Source, Inc. | 9.25 Million USD | 79.199% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 28.933% |
| GeneThera, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -859.545% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | 2.19 Million USD | 12.495% |
| Kadimastem Ltd | 891.22 Thousand USD | -115.995% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -812.43% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -669.44% |
| LadRx Corporation | 33.6 Thousand USD | -5628.144% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -154.561% |
| Affymax, Inc. | - USD | -Infinity% |
| Itoco Inc. | 228.37 Thousand USD | -742.904% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | 61.369% |
| Mobile Lads Corp. | 484.28 Thousand USD | -297.494% |
| International Stem Cell Corporation | 4.17 Million USD | 53.925% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | -447.113% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | 75.384% |
| SYBLEU INC | 477.5 Thousand USD | -303.141% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -1471.429% |
| Rebus Holdings, Inc. | 310 Thousand USD | -520.968% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | 59.348% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -2984.293% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 11.734% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | 76.852% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | 77.577% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | -23.756% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -618.284% |
| Neutra Corp. | 54.15 Thousand USD | -3454.546% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | -5.191% |
| PureTech Health plc | 25.51 Million USD | 92.455% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | -57.242% |
| IXICO plc | 472.02 Thousand USD | -307.819% |
| IntelGenx Technologies Corp. | 15.5 Million USD | 87.581% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 96.908% |
| CSL Limited | 12.18 Billion USD | 99.984% |
| Cellectis S.A. | 92.77 Million USD | 97.925% |